Respiratory syncytial virus infections – recent developments providing promising new tools for disease prevention

References

1. European Medicines Agency (EMA). First RSV vaccine to protect infants up to 6 months of age and older adults: EMA; 21 Jul 2023. Available from: https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults
2. European Medicines Agency (EMA). Beyfortus (nirsevimab) - An overview of Beyfortus and why it is authorised in the EU. Amsterdam: EMA; 2023. Available from: https://www.ema.europa.eu/en/documents/overview/beyfortus-epar-medicine-overview_en.pdf
3. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64.  https://doi.org/10.1016/S0140-6736(22)00478-0  PMID: 35598608 
4. Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53.  https://doi.org/10.1016/S2213-2600(22)00414-3  PMID: 36372082 
5. Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J Infect Dis. 2022;226(Suppl 1):S29-37.  https://doi.org/10.1093/infdis/jiac150  PMID: 35748871 
6. van Wijhe M, Johannesen CK, Simonsen L, Jørgensen IM, Fischer TK, Fischer TK, RESCEU Investigators. A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus. J Infect Dis. 2022;226(Suppl 1):S55-62.  https://doi.org/10.1093/infdis/jiac141  PMID: 35426942 
7. Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Bøås H, et al. Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union. J Infect Dis. 2023;228(11):1539-48.  https://doi.org/10.1093/infdis/jiad189  PMID: 37246742 
8. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Euro). Operational considerations for respiratory virus surveillance in Europe. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/operational-considerations-respiratory-virus-surveillance-europe
9. Iglesias-Caballero M, Camarero-Serrano S, Varona S, Mas V, Calvo C, García ML, et al. Genomic characterisation of respiratory syncytial virus: a novel system for whole genome sequencing and full-length G and F gene sequences. Euro Surveill. 2023;28(49):2300637.  https://doi.org/10.2807/1560-7917.ES.2023.28.49.2300637 
10. Ramaekers K, Rector A, Cuypers L, Lemey P, Keyaerts E, Van Ranst M. Towards a unified classification for human respiratory syncytial virus genotypes. Virus Evol. 2020;6(2):veaa052.  https://doi.org/10.1093/ve/veaa052  PMID: 33072402 
11. Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023;28(49):2300606.  https://doi.org/10.2807/1560-7917.ES.2023.28.49.2300606 
12. De Luca D, Sanchez-Luna M, Schettler K, Bont L, Baraldi E. Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt. Lancet Reg Health Eur. 2023;34:100753.  https://doi.org/10.1016/j.lanepe.2023.100753  PMID: 37927432 
13. PATH. RSV Vaccine and mAb Snapshot. 21 Sep 2023. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/
14. European Centre for Disease Prevention and Control (ECDC). Intensified circulation of respiratory syncytial virus (RSV) and associated hospital burden in the EU/EEA. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/intensified-circulation-respiratory-syncytial-virus-rsv-and-associated-hospital
15. Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759.  https://doi.org/10.1186/s12879-022-07745-0  PMID: 36175846 
16. Li X, Hodgson D, Flaig J, Kieffer A, Herring WL, Beyhaghi H, et al. Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study. Value Health. 2023;26(4):508-18.  https://doi.org/10.1016/j.jval.2022.11.014  PMID: 36442831 
17. Getaneh AM, Li X, Mao Z, Johannesen CK, Barbieri E, van Summeren J, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine. 2023;41(9):1623-31.  https://doi.org/10.1016/j.vaccine.2023.01.058  PMID: 36737318 
18. Turalde-Mapili MWR, Mapili JAL, Turalde CWR, Pagcatipunan MR. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis. Front Pediatr. 2023;11:1132740.  https://doi.org/10.3389/fped.2023.1132740  PMID: 37082704 
19. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-64.  https://doi.org/10.1056/NEJMoa2216480  PMID: 37018474 
20. European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC. [Accessed: 24 Nov 2023]. Available from: https://erviss.org/